Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 9/20 | 0.34 |
| ▸ | MDM4 | O15151 | 8/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16437157 | 0.92 | CYP1A2 (0.31) | CYP3A4 | |
| SCHEMBL16437161 | 0.91 | GRM7 (0.32) | FGFR1 | |
| SCHEMBL16437466 | 0.84 | MAPT (0.33) | CYP3A4TP53 | |
| SCHEMBL17804243 | 0.83 | IL6 (0.33) | — | |
| SCHEMBL17804257 | 0.83 | — | — | |
| SCHEMBL16437153 | 0.83 | P2RX3 (0.33) | — | |
| SCHEMBL16385114 | 0.82 | MRGPRX4 (0.34) | MDM2MDM4CYP3A4TP53 | |
| SCHEMBL17811657 | 0.82 | RXRA (0.32) | — | |
| SCHEMBL16437284 | 0.81 | SMN1; SMN2 (0.35) | CYP3A4TP53 | |
| SCHEMBL17804266 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3029035-B1 | TETRAZOLINONE COMPOUND, AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9521848-B2 | Tetrazolinone compound and use therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029035-A1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | CYP51A1, CYP4F11, CYP1B1 | MDM2 742/4885MDM4 4536/4885DPP4 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.